Shortening letermovir for CMV prevention after transplant
Part of Infections clinical trials.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a half-matched (haploidentical) stem cell transplant from a family member.
- Your CMV test before transplant was positive (or your donor had CMV and you didn't).
- You have been taking the anti-CMV drug letermovir since transplant without stopping.
- Your CMV blood test is negative right now (within the last 5 days).
- You are 18 years or older and can give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.